Evidence map›Paper›PMID 26579443›Full record

ReviewActa pharmaceutica Sinica. B2015

Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment.

Lin Kang, Zhonggao Gao, Wei Huang, Mingji Jin, Qiming Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Poly(caprolactone)-Polymers · 2022
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lin KangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Zhonggao GaoState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Wei HuangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Mingji JinState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Qiming WangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of chemotherapeutic drug in cancer treatment is often hampered by drug resistance of tumor cells, which is usually caused by abnormal gene expression. RNA interference mediated by siRNA and miRNA can selectively knock down the carcinogenic genes by targeting specific mRNAs. Therefore, combining chemotherapeutic drugs with gene agents could be a promising strategy for cancer therapy. Due to poor stability and solubility associated with gene agents and drugs, suitable protective carriers are needed and have been widely researched for the co-delivery. In this review, we summarize the most commonly used nanocarriers for co-delivery of chemotherapeutic drugs and gene agents, as well as the advances in co-delivery systems.

Indexed as

ANG-CLP, angiopep-2 modified cationic liposomeChemotherapeutic drugCMC, critical micelle concentrationCo-deliveryCPLA, cationic polylactideDendrimerDOTAP, 1,2-dioleoyl-3-trimethylammonium-propaneFA, folic acidFCAP, ferrocenium capped amphiphilic pillar[5]areneGeneGSH, glutathioneLiposomeMicellemiRNA, micro-RNANanocarrierOEI, oligoethyleniminePAMAM, poly(amido amine)PAsp(AED), poly(N-(2,2ʹ-dithiobis(ethylamine))aspartamide)PCL, poly(ε-caprolactone)PDMAEMA, polydimethylaminoethyl methacrylatePDPA, poly(2-(diisopropyl amino)ethyl methacrylate)PEG, polyethyleneglycolPEI-Fc, ferrocene modified poly(ethyleneimine)PEI-PCHLG, poly(ethylene imine)-poly(γ-cholesterol-l-glutamate)PEI-PCL, poly(ethyleneimine) and poly(ε-caprolactone)PEI, poly(ethyleneimine)PLA, polylactic acid (or polylactide)PLGA, poly(lactic-co-glycolic acid)PnBA, poly(n-butyl acrylate)PPEEA, poly(2-aminoethyl ethylene phosphate)RNAi, RNA interferencesiRNA, small interfering RNAsiVEGF, VEGF-targeted siRNASNPs, supramolecular nanoparticlesSSTRs, somatostatin receptors poly(N-(2,2′-dithiobis(ethylamine))aspartamide)Supramolecular systemγ-CD, γ-cyclodextrin

Identifiers

PMID26579443
PMCPMC4629232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.